Expert Perspectives on Advances in the Management of C. difficile - Episode 13

C. Difficile Treatment: Bezlotoxumab

January 8, 2021

The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.

EP. 1: C. Difficile Risk Factors and Manifestation

EP. 2: Strains of C. Difficile

EP. 3: Managing Community-Onset C. Difficile

EP. 4: Recurrent C. Difficile

EP. 5: C. Difficile: A Differential Diagnosis

EP. 6: Testing for C. Difficile Infections

EP. 7: Screening for C. Difficile

EP. 8: C. Difficile: Clinical Practice Guidelines and Treatment Options

EP. 9: C. Difficile: Updates to Clinical Practice Guidelines

EP. 10: Selecting Therapy to Treat C. Difficile

EP. 11: C. Difficile Treatment: Fidaxomicin

EP. 12: Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections

Now Viewing

EP. 13: C. Difficile Treatment: Bezlotoxumab

EP. 14: Preventing/Treating C. Difficile: Unmet Needs

EP. 15: Fecal Microbiota Transplantation for C. Difficile Infections

EP. 16: Emerging Treatment Options for C. Difficile Infections

EP. 17: C. Difficile: Barriers Treating With FMT

EP. 18: Making Strides in the Management of C. Difficile